ONE NUCLEUS STRENGTHENS BOARD WITH APPOINTMENT OF NEW DIRECTOR

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
Associate Principal Scientist – Large Molecule Bioanalysis
UK – Hoddesdon
Pharmaron is a leading global Contract Research Organisation (CRO), supporting pharmaceutical and biotechnology companies across the full drug discovery and development lifecycle. With more than 25,000 employees across 23 sites in the UK, US, and China, we deliver fully integrated scientific services that help accelerate the development of novel therapies.
Company Description
This role is centred on providing scientific leadership and oversight of all the technical aspects within the local Fordham immunoassay group, and throughout the wider Resolian immunoassay teams.
You will be responsible for providing supervision, guidance, and expertise, in order to facilitate the delivery of high quality methods and sample analysis results to our customers in compliance with GLP/GCP.
bit.bio is an award-winning spinout from the University of Cambridge. Our breakthrough technology combines synthetic and stem cell biology for the precise, efficient and consistent reprogramming of human cells used in research, drug discovery, and cell therapy. At bit.bio, we are passionate about engineering human cells that will enable the medicine of the future. To do this we need talented and curious people who want to make an impact on the future of science and therapeutics.
About the role:
LifeArc is a self-funded not-for-profit medical research organisation.
We have our own sources of income and therefore do not rely on fundraising or external grants to support our work. One key source is our main investment portfolio.
This new role will support our growing Investment team in the implementation of the investment strategy and mandate to ensure LifeArc outperforms its investment objective while in keeping with its sustainability goals and charitable objectives.
LONDON, UK – April 16, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Babraham Research Campus Ltd (BRCL) and is pleased to announce the placement of Dr. Rich Ferrie as Chief Executive Officer (CEO).
Some of the UK’s most ambitious early-stage life science companies are choosing Victoria House as their London base, adding fresh momentum to one of the capital’s most exciting life science communities.
Developed by Oxford Properties and Pioneer Group, the Bloomsbury Square building has attracted 24 innovative organisations since it launched last year, drawn by a rare and unique combination of high-quality incubator labs, flexible workspace, and a genuinely collaborative community.
Companies confirm that markers of weight loss and glycemic control are distinct in preliminary study, with multiple mechanisms identified that provide opportunities to guide indication extension